The past, present and future of renin-angiotensin aldosterone system inhibition

Robert J. Mentz, George L. Bakris, Bernard Waeber, John J V McMurray, Mihai Gheorghiade, Luis M. Ruilope, Aldo P. Maggioni, Karl Swedberg, Ileana L. Pina, Mona Fiuzat, Christopher M. O'Connor, Faiez Zannad, Bertram Pitt

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.

Original languageEnglish (US)
Pages (from-to)1677-1687
Number of pages11
JournalInternational Journal of Cardiology
Volume167
Issue number5
DOIs
StatePublished - Sep 1 2013

Fingerprint

Renin-Angiotensin System
Heart Failure
Myocardial Infarction
Hypertension
Atrial Fibrillation
Cardiovascular Diseases
History
Clinical Trials
Blood Pressure
Drug Therapy

Keywords

  • Clinical trials
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Renin-angiotensin aldosterone system

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mentz, R. J., Bakris, G. L., Waeber, B., McMurray, J. J. V., Gheorghiade, M., Ruilope, L. M., ... Pitt, B. (2013). The past, present and future of renin-angiotensin aldosterone system inhibition. International Journal of Cardiology, 167(5), 1677-1687. https://doi.org/10.1016/j.ijcard.2012.10.007

The past, present and future of renin-angiotensin aldosterone system inhibition. / Mentz, Robert J.; Bakris, George L.; Waeber, Bernard; McMurray, John J V; Gheorghiade, Mihai; Ruilope, Luis M.; Maggioni, Aldo P.; Swedberg, Karl; Pina, Ileana L.; Fiuzat, Mona; O'Connor, Christopher M.; Zannad, Faiez; Pitt, Bertram.

In: International Journal of Cardiology, Vol. 167, No. 5, 01.09.2013, p. 1677-1687.

Research output: Contribution to journalArticle

Mentz, RJ, Bakris, GL, Waeber, B, McMurray, JJV, Gheorghiade, M, Ruilope, LM, Maggioni, AP, Swedberg, K, Pina, IL, Fiuzat, M, O'Connor, CM, Zannad, F & Pitt, B 2013, 'The past, present and future of renin-angiotensin aldosterone system inhibition', International Journal of Cardiology, vol. 167, no. 5, pp. 1677-1687. https://doi.org/10.1016/j.ijcard.2012.10.007
Mentz RJ, Bakris GL, Waeber B, McMurray JJV, Gheorghiade M, Ruilope LM et al. The past, present and future of renin-angiotensin aldosterone system inhibition. International Journal of Cardiology. 2013 Sep 1;167(5):1677-1687. https://doi.org/10.1016/j.ijcard.2012.10.007
Mentz, Robert J. ; Bakris, George L. ; Waeber, Bernard ; McMurray, John J V ; Gheorghiade, Mihai ; Ruilope, Luis M. ; Maggioni, Aldo P. ; Swedberg, Karl ; Pina, Ileana L. ; Fiuzat, Mona ; O'Connor, Christopher M. ; Zannad, Faiez ; Pitt, Bertram. / The past, present and future of renin-angiotensin aldosterone system inhibition. In: International Journal of Cardiology. 2013 ; Vol. 167, No. 5. pp. 1677-1687.
@article{4f133109adf343209e263941b3590049,
title = "The past, present and future of renin-angiotensin aldosterone system inhibition",
abstract = "The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.",
keywords = "Clinical trials, Heart failure, Hypertension, Myocardial infarction, Renin-angiotensin aldosterone system",
author = "Mentz, {Robert J.} and Bakris, {George L.} and Bernard Waeber and McMurray, {John J V} and Mihai Gheorghiade and Ruilope, {Luis M.} and Maggioni, {Aldo P.} and Karl Swedberg and Pina, {Ileana L.} and Mona Fiuzat and O'Connor, {Christopher M.} and Faiez Zannad and Bertram Pitt",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.ijcard.2012.10.007",
language = "English (US)",
volume = "167",
pages = "1677--1687",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "5",

}

TY - JOUR

T1 - The past, present and future of renin-angiotensin aldosterone system inhibition

AU - Mentz, Robert J.

AU - Bakris, George L.

AU - Waeber, Bernard

AU - McMurray, John J V

AU - Gheorghiade, Mihai

AU - Ruilope, Luis M.

AU - Maggioni, Aldo P.

AU - Swedberg, Karl

AU - Pina, Ileana L.

AU - Fiuzat, Mona

AU - O'Connor, Christopher M.

AU - Zannad, Faiez

AU - Pitt, Bertram

PY - 2013/9/1

Y1 - 2013/9/1

N2 - The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.

AB - The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.

KW - Clinical trials

KW - Heart failure

KW - Hypertension

KW - Myocardial infarction

KW - Renin-angiotensin aldosterone system

UR - http://www.scopus.com/inward/record.url?scp=84883263452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883263452&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2012.10.007

DO - 10.1016/j.ijcard.2012.10.007

M3 - Article

VL - 167

SP - 1677

EP - 1687

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 5

ER -